Hybridon to Get $5 Million for Cancer Programs

Hybridon has entered into definitive agreements with investors in connection with a private financing of $5 million to help fund the company's cancer programs. The company expects to use the proceeds of the financing to fund its toll-like receptor 9 (TLR9) drug development activities, including an ongoing phase II trial of IMOxine in renal cell carcinoma and a new Phase I/II clinical trial of IMOxine in combination with chemotherapy in non-small cell lung cancer.

()a href="http://www.pharmaceutical-business-review.com/article_news.asp?guid=2C168965-F215-4495-BE9A-570D8C4908E6" target="_blank">Pharmaceutical Business Review Online